ERYP - ERYTECH Pharma S.A.
| Previous Close | 4.0200 |
| Open | 3.9458 |
| Bid | 2.1000 x 1400 |
| Ask | 0.0000 x 800 |
| Day's Range | 4.0000 - 4.0200 |
| 52 Week Range | 3.9460 - 10.6500 |
| Volume | 0 |
| Avg. Volume | 476 |
| Market Cap | 74.272M |
| Beta (3Y Monthly) | 1.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.7860 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.59 |
- GlobeNewswire
Monthly information related to total number of voting rights and shares composing the share capital – September 30, 2019
LYON, France, Oct. 04, 2019 -- Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in.
- GlobeNewswire
ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2019
ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business update and reported its financial results for the quarter ended June 30, 2019. “The second quarter of 2019 remained focused on the execution of our late stage clinical trials of eryaspase and the extension of our manufacturing capacity. Patient enrollment in TRYbeCA 1, our pivotal Phase 3 trial in second-line metastatic pancreatic cancer, continues at a strong pace in Europe, and we expect enrollment in the United States to begin shortly,” said Gil Beyen, CEO of ERYTECH.
- GlobeNewswire
ERYTECH to Host Second Quarter 2019 Conference Call and Business Update
LYON, France, Sept. 11, 2019 -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by.
- GlobeNewswire
Monthly information related to total number of voting rights and shares composing the share capital – August 31, 2019
LYON, France, Sept. 03, 2019 -- Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market.
- GlobeNewswire
Monthly information related to total number of voting rights and shares composing the share capital – July 31, 2019
LYON, France, Aug. 02, 2019 -- Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in.
- GlobeNewswire
ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 21, 2019
LYON, France and CAMBRIDGE, Mass., July 16, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP) announced that its 2019 Annual General Meeting was held in Paris on Friday, June 21, 2019.
- GlobeNewswire
Erytech Pharma S.A. : Monthly information related to total number of voting rights and shares composing the share capital - September 30, 2018
Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon - France Listing markets: Euronext Paris from Euronext (Market segment B - ISIN Code: FR0011471135- Symbol: ERYP) & ...
- GlobeNewswire
Monthly information related to total number of voting rights and shares composing the share capital – June 30, 2019
LYON, France, July 02, 2019 -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext.
- GlobeNewswire
ERYTECH Announces Enrollment of First Patient in Phase 2 Clinical Trial Evaluating Eryaspase in TNBC
ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that the first patient has been enrolled in its Phase 2 clinical trial, named TRYbeCA2, evaluating its lead product candidate eryaspase for the treatment of first line triple negative breast cancer (TNBC). Following the positive Phase 2 results with eryasaspase in second-line metastatic pancreatic cancer, ERYTECH selected triple-negative breast cancer as the next indication to expand the potential use of eryaspase in solid tumors.
- GlobeNewswire
ERYTECH Announces Immune Modulation Strategic Collaboration with SQZ Biotechnologies
LYON, France and CAMBRIDGE, Mass., June 24, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (ERYTECH) (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells (RBCs), announced today that it has entered into an agreement with SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments in multiple therapeutic areas, to advance novel RBC-based therapeutics for immune modulation. Under the terms of the agreement, ERYTECH has granted to SQZ an exclusive worldwide license to develop antigen-specific immune modulating therapies employing RBC-based approaches. Combining SQZ`s proprietary and versatile cell engineering platform, Cell Squeeze®, with ERYTECH`s intellectual property related to RBC-based therapeutics is intended to allow for the rapid development of a broad pipeline of novel immunomodulatory products addressing multiple indications.
- GlobeNewswire
ERYTECH Announces Opening of Operations at its New Princeton, NJ GMP Manufacturing Facility
PRINCETON, N.J. and CAMBRIDGE, Mass. and LYON, France, June 24, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, announced today the opening of its new Princeton, NJ GMP manufacturing facility. The facility will support production capacity needs for eryaspase, the Company`s lead product candidate for patients in the United States.
- GlobeNewswire
ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 21, 2019
LYON, France, May 31, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug ...
- GlobeNewswire
ERYTECH Announces FDA's Authorization to Proceed with Phase 3 Trial for Eryaspase in Pancreatic Cancer in the United States
LYON, France and CAMBRIDGE, Mass. , May 13, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced the acceptance by the US Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for eryaspase, consisting of the enzyme L-asparaginase encapsulated inside donor derived red blood cells. The acceptance of the IND will enable ERYTECH to initiate enrollment at US trial sites for its ongoing pivotal Phase 3 TRYbeCA1 trial evaluating eryaspase in second-line pancreatic cancer. TRYbeCA1 is expected to enroll approximately 500 patients with second-line metastatic pancreatic cancer at more than 120 clinical sites in Europe and the United States.
- GlobeNewswire
ERYTECH Announces FDA’s Authorization to Proceed with Phase 3 Trial for Eryaspase in Pancreatic Cancer in the United States
ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced the acceptance by the US Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for eryaspase, consisting of the enzyme L-asparaginase encapsulated inside donor derived red blood cells. The acceptance of the IND will enable ERYTECH to initiate enrollment at US trial sites for its ongoing pivotal Phase 3 TRYbeCA1 trial evaluating eryaspase in second-line pancreatic cancer. TRYbeCA1 is expected to enroll approximately 500 patients with second-line metastatic pancreatic cancer at more than 120 clinical sites in Europe and the United States.
- GlobeNewswire
ERYTECH Provides Business Update and Reports Financial Results for First Quarter 2019
Conference call and webcast on Tuesday, May 7 at 2:30 pm CET/8:30 am EDT TRYbeCA1, pivotal Phase 3 trial for eryaspase in second line pancreatic cancer, actively enrolling patients Construction of new ...
- GlobeNewswire
ERYTECH proposes the appointment of Dr. Jean-Paul Kress as Chairman of the Board of Directors
LYON, France, May 06, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic ...
- GlobeNewswire
ERYTECH to Host on May 7, 2019 First Quarter Conference Call and Business Update
Lyon (France), March 2, 2019 - ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances ...